Trial Profile
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2023
Price :
$35
*
At a glance
- Drugs Lifileucel (Primary) ; LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Ipilimumab; Nivolumab; Pembrolizumab
- Indications Adenocarcinoma; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 12 Sep 2023 Results (As of 21 Mar 2023) assessing efficacy and safety data for LN-145 autologous TIL cell therapy in combination with pembrolizumab in patients with ICI naive metastatic NSCLC presented at the 24th World Conference on Lung Cancer
- 25 Jul 2023 According to an Iovance Biotherapeutics media release, cohort 3A data of LN-145 in Combination with Pembrolizumab in Anti-PD1-naive Advanced (metastatic or unresectable) Non-Small Cell Lung Cancer (NSCLC) will be presented as an oral presentation at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
- 23 Jan 2023 According to an Iovance Biotherapeutics media release, the company plans to meet with FDA in 2023 to discuss Cohort 3A results and a potential registration trial of lifileucel in frontline advanced NSCLC patients who are EGFR wild-type.